Engineering Approach
Target KO antibody Contruction Lentivirus
Alternative Names
B7-H; B7H1; PDL1; PD-L1; hPD-L1; PDCD1L1; PDCD1LG1
Introduction
This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants.
Applications
Resistant to reprogramming by tumor-secreted signals
Reference
Moyes, Kara W et al. "Genetically Engineered Macrophages: A Potential Platform for Cancer Immunotherapy." Human gene therapy vol. 28,2 (2017): 200-215. doi:10.1089/hum.2016.060
Datasheet